NASDAQ 100 % ()
FTSE 100 % ()
DOLLAR INDEX % ()
BTC/USD % ()
EUR/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()
CRUDE OIL % ()

JNJ

Johnson & Johnson New York Stock Exchange
$170.37
Open: $164.5 High: $173.65 Low: $163.66 Close: $170.256
Range: 2021-01-25 - 2021-01-26
Volume: 20,674,484
Market: Open
Powered by Finage Stock APIDelayed data
JNJ
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick NJ, 8933 http://www.jnj.com
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
  • CEO: Alex Gorsky
  • Employees: 134,000
  • Sector: Healthcare
  • Industry: Drug Manufacturers
JNJ News
Latest news about the JNJ
  • Dow Jones, S&P 500 Up Slightly After Giving Up Gains; Microsoft In Buy Zones Ahead Of Earnings

    The Dow Jones Industrial Average traded around breakeven in today's stock market, while the S&P 500 edged up from earlier highs of the day.

    View More →
  • Coronavirus update: J&J to release vaccine data next week; strain from Brazil confirmed in US

    Johnson and Johnson expects vaccine data next week.

    View More →
  • Markets continue to flitter between stimulus hope and COVID concerns: strategist

    AlphaSimplex Portfolio Manager and Chief Research Strategist Kathryn Kaminski joins Yahoo Finance Live to break down how markets are faring amid pandemic and this weeks earnings haul.

    View More →
  • J&J CEO: Expect Phase 3 results for its COVID-19 vaccine candidate early next week

    Johnson & Johnson expects to share details from the Phase 3 clinical trial for its COVID-19 vaccine candidate "early next week," according to remarks made by CEO Alex Gorsky on Tuesday during an earnings call. J&J's stock was up 3.0% in trading on Tuesday afternoon. The company's experimental COVID-19 adenovirus-based vaccine is currently being tested in late-stage clinical trials, and results are being closely watched for several reasons, including that it's a single-dose vaccine and there are ongoing supply issues for doses of the BioNTech SE /Pfizer Inc. and Moderna Inc. vaccines in the U.S. (Both of the currently authorized coronavirus vaccines in the U.S. require two doses.) "We're certainly hopeful that you're going to see a durable and a sustainable and patent response, particularly from our [adenovirus-based] vector approach," Gorsky told investors, according to a FactSet transcript of the call. J&J's stock is up 15.3% over the past 12 months, while the S&P 500 has gained 17.0%.

    View More →
  • Companies beating estimates ‘bodes well’ for the rest of earnings season: WealthWise Financial CEO

    WealthWise Financial CEO Loreen Gilbert joins Yahoo Finance Live to discuss the latest market action as earnings season continues.

    View More →
  • J&J Will Report on Covid-19 Vaccine’s Efficacy Within Days

    Information on how the single-dose vaccine works against new variants of the coronavirus may be available as well.

    View More →
  • Dow Slips With Biden Open To This Stimulus Compromise; Microsoft, GE Hits Buy Zone

    The Dow Jones rallied early as it emerged that President Joe Biden could be open to slicing his coronavirus stimulus package. Microsoft stock and GE stock flashed buy signals.

    View More →
  • Johnson & Johnson CFO on COVID-19 vaccine: ‘We are very much on track to meet the capacity requirements’

    Johnson & Johnson reported fourth quarter earnings that beat expectations. Johnson & Johnson CFO Joe Wolk joins Yahoo Finance Live to discuss.

    View More →
  • Here's Why Investors Cheered Johnson & Johnson's Q4 Results

    Johnson & Johnson (NYSE: JNJ) delivered a return of nearly 8% in 2020. Adding in the company's dividend gives a total return of close to 11%. Here are the highlights from Johnson & Johnson's Q4 update.

    View More →
  • J&J Forecast Tops Views, Even Excluding Vaccine; Shares Gain

    (Bloomberg) -- Johnson & Johnson issued a stronger-than-expected earnings forecast for this year, but its outlook didn’t say how its Covid-19 vaccine, which could be cleared for use in the U.S. soon, would affect its performance.The health-care giant expects 2021 adjusted earnings per share of $9.49 to $9.60, compared with an average analyst estimate of $8.99.Strong sales for blockbuster immunology and cancer drugs, as well as consumer-health products such as Tylenol and Listerine, have buoyed the company in recent quarters even as the pandemic hurt sales of medical devices.J&J will likely adjust its guidance in April, when it reports first-quarter earnings, to account for its Covid-19 vaccine, Chief Financial Officer Joseph Wolk said in an interview. He said the company expects to report clinical-trial data on the still-expiremental shot’s efficacy by early next week.“Our outlook is solid, just based on our core business, irrespective of the vaccine,” Wolk said. “Our guidance doesn’t include any distribution of vaccines at this point, and again, we’re going to be offering it on a not-for-profit basis, so you’re not gonna get the same type of margins on any sales of it.”Shares of Johnson & Johnson rose 3% to $170.92 at 10:48 in New York on Tuesday. Through the close Monday, the stock had gained 5.46% so far this year.Vaccine ProspectsJ&J’s progress is being closely watched by top infectious-disease experts because its vaccine would be the first to protect people after one shot, which is expected to make mass-vaccination campaigns easier. The vaccine generated a lasting immune response in an early study. According to the company’s top scientist, U.S. regulators could authorize it for emergency use in March.The shot will be priced on a not-for-profit basis, defined by a Gates Foundation model and determined in conjunction with independent auditors, Wolk said. The price per shot will not exceed $10 dollars.Wolk said J&J aims to have a total of seven manufacturing facilities, many of which are contract manufacturers, up and running by the end of the second quarter to ramp up supply. The company told Bloomberg earlier this month that it remains on track to hit the goal of producing 1 billion doses before year-end.Surging SalesThe New Brunswick, New Jersey-based company’s fourth-quarter revenue was $22.5 billion, surpassing the $21.67 billion analysts expected, on average.Pharmaceutical sales surged 16% in the fourth quarter from a year earlier, topping $12.3 billion. The gains were driven by three blockbusters: Stelara, used to treat Crohn’s disease and psoriasis, and cancer treatments Imbruvica and Darzalex. Drug sales rose 8% for the full year.“We think this trend will continue,” Wolk said, “and we’re going to supplement the existing portfolio that exists today with new products. We’ve got a couple of new launches in the oncology space that we feel really good about.”The consumer unit saw more modest 1.4% growth in the fourth quarter, bringing in $3.6 billion. Throughout the year, demand for J&J’s beauty and baby-care products was hurt by Covid-19, though that was offset by pandemic stockpiling for products like Tylenol and Listerine.The pandemic continued to restrain J&J’s medical-device sales in the fourth quarter, with sales down 0.7% to $6.6 billion compared with a year earlier. For the full year, device sales dropped 10.5%.Wolk said he expects some of the pandemic’s effects on hospitals to “spill over into the first month or so of 2021.” But as the year progresses and more people in the U.S. are vaccinated against Covid-19, elective surgeries will continue rebound, he said. At that point, J&J will benefit from the pent-up demand for its medical devices.“2020 was obviously a bumpy year, but we never took our focus off the long-term,” Wolk said. J&J spent a record $12 billion on research and development amid the pandemic.(Updates shares, and adds additional comments from chief financial officer about vaccine pricing)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

    View More →
  • Johnson & Johnson Shares Pop on Stronger-Than-Expected 4th-Quarter Results

    Pharmaceutical giant provides strong 2021 guidance

    View More →
  • Johnson & Johnson (JNJ) Surges to All-Time High

    Johnson & Johnson (JNJ) stock has rallied to an all-time high in reaction to a strong quarter and next week's vaccine data release.

    View More →
  • Home Prices Rose in November

    Home Prices Rose in November

    View More →
  • Housing Charges Economy: +9.5% Case Shiller & DHI's Earnings Beat

    Record-low interest rates, along with Americans moving away from the big cities, helped lead the housing formation run.

    View More →
  • US STOCKS-S&P 500 scales new high on upbeat corporate earnings

    U.S. stocks rose on Tuesday with the S&P 500 hitting another record high as positive earnings updates from a slew of companies including Dow components 3M and Johnson & Johnson supported sentiment. Johnson & Johnson rose 3.6% after the drugmaker forecast 2021 profit above estimates and promised data from its widely watched coronavirus vaccine trial soon. "So far earnings have been really strong and the market is looking forward to some of the big tech names starting to report earnings today," said Ross Mayfield, investment strategy analyst at Baird, in Milwaukee.

    View More →
  • J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat

    J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.

    View More →
  • Johnson & Johnson Tops Q4 Earnings Forecast; Will Publish Vaccine Update 'Soon'

    Johnson & Johnson CEO Alex Gorsky said the group "continues to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon."

    View More →
  • Dow Jones Today, Stocks Tick Higher As Earnings Lift J&J, 3M, GE; And Elon Musk Loves Etsy

    Etsy and 360 Digitech staked early leads, J&J propped the Dow Jones today, as stocks edged up in a tentative open on Tuesday.

    View More →
  • Earnings Continue With Johnson & Johnson, 3M Early, Followed By Microsoft Later

    Trying to keep up with all the earnings news? It’s a challenge, but a welcome one for many investors anxious to see how Q4 turned out for the major companies. The day begins with a fresh batch of earnings data but nothing new on the vaccine front. Johnson & Johnson (NYSE: JNJ) had really nice earnings and so did Raytheon Technologies Corp (NYSE: RTX). Meanwhile, Microsoft Corporation (NASDAQ: MSFT), Texas Instruments Incorporated (NASDAQ: TXN) and Starbucks Corporation (NASDAQ: SBUX) wait in the wings for after the close. There’s so much to look at today it’s hard to keep track of everything. Some investors might have been hoping for a vaccine update from JNJ as part of its earnings today. Instead, the company promised results, “soon.” With a lot of people worried about new virus variants and slower than expected ramp-up of vaccinations, any positive news on JNJ’s vaccine would probably be welcomed. Looks like we’ll have to wait a bit longer. We won’t have to wait much longer for the latest Fed observations. They start their meeting today and Chairman Jerome Powell takes the podium tomorrow afternoon. There’s not much drama here. It would be shocking if the Fed said anything other than what it’s been saying about keeping things dovish so the economy can recover. It is the Fed, so you have to pay attention, and of course consider listening for anything they say about possible inflation. Otherwise, it’s probably going to be like sitting through the same movie you just watched. Yesterday, “risk-off” trading dominated. Bonds and volatility rose amid virus worries. Today, bonds stepped back just a bit, crude is holding steady, and markets in Europe rose overnight amid strong earnings over there. That, combined with the morning’s solid set of U.S. earnings reports, might explain the light pre-market gains for some of the major indices. Toilet Paper And Canned Stew On the first day of the biggest earnings week of the year, what rallied? Companies that make toilet paper, household cleaners, and canned beef stew. Kimberly Clark Corp (NYSE: KMB), Clorox Co (NYSE: CLX), and Hormel Foods Corp (NYSE: HRL) partied like it was 2020 on Monday. At the same time, big-Tech got some bids ahead of Microsoft Corporation (NASDAQ: MSFT) reporting later today and Apple Inc (NASDAQ: AAPL), Tesla Inc (NASDAQ: TSLA), and Facebook, Inc. (NASDAQ: FB) going tomorrow. Basically, the market behaved like everyone would be staying home a while longer, with investors once again embracing the stocks that rocked when lockdowns first hit. Meanwhile, the airlines that had found some buyers last week got sent back to the hangar, with American Airlines Group Inc (NASDAQ: AAL), Delta Air Lines, Inc. (NYSE: DAL), and United Airlines Holdings Inc (NASDAQ: UAL) suffering sharp losses. At the same time, bonds also received some new love, pushing the 10-year Treasury yield down to 1.03% by the end of the day after it touched 1.19% earlier this month. Right now, yields might remind you of a turtle that stuck its head out from under its shell, sniffed the air, and then decided it was safer inside. The yield is at its lowest level since Jan. 6. All this could mean there’s trepidation about the pandemic, especially with Europe facing more trouble and new strains in the U.K. and South Africa. Carnival Corp (NYE:CCL) pushed back cruises. Also, the Biden administration’s decision yesterday to suspend travel to the U.S. from some countries helped reinforce that we’re far from being out of the woods. The Cboe Volatility Index (VIX) climbed above 24 for a while yesterday after dropping below 22 at times last week, a possible sign of investors fearing more choppiness in the coming days. The “risk-off” mood might have gained strength by having 20% of the S&P 500 reporting this week and slow progress on vaccinations here. The market’s had an incredible run and many analysts worry things have gotten a little bit priced for perfection. There’s also concern that the Biden administration’s stimulus package might be pushed back on the calendar or trimmed, as it continues to face resistance in Congress. This could have been a factor pressing on some of the cyclical sectors yesterday like Financials and Energy, research firm Briefing.com noted. What Goes Up... Gamestop’s Wild Session Also, when you observe action like we saw in GameStop Corp. (NYSE: GME) yesterday, you start to scratch your head a little. The stock more than doubled at one point and trading had to be halted several times for volatility. Like it or not, this is the type of stuff that makes veteran investors think back to the crazy days of 1999 and 2000. GME is up another 14% in pre-market trading. It’s not too hard to find analysts who believe GME is trading far beyond its fundamentals, and there was talk that Monday’s move might have reflected a “short squeeze.” Sometimes a short squeeze is followed by more buying, which was apparently the case last year with TSLA. It can also indicate lots of people with deep pockets not necessarily investing in a stock, but trading it. There’s nothing wrong with that, but if you’re a long-term investor it’s probably not a great idea to get too deeply involved in these moves. This is not normal activity, and you also have to be careful that when the music stops, so to speak—or when these buyers stop and it becomes like a game of musical chairs—that you’re not the one stuck without a chair and nowhere to turn to sell. The momentum that caused GME to go up can also be the momentum that causes it to go down, very quickly. Caution is the watchword, for GME and many other stocks that have been making new highs. Earnings could be the time when companies need to offer proof that their high prices are justified by the fundamentals. Looking ahead to this afternoon’s fundamentals, MSFT earnings could go a long way toward starting to tell the broader Tech story. Analysts expect the company’s commercial cloud segment to again be the main driver, with focus as always on Azure, MSFT’s main cloud platform. Azure sales grew 48% in the prior quarter, outrunning Wall Street’s estimates. We’ll see what sort of encore MSFT reports today. Starbucks Corporation (NASDAQ: SBUX) is a big company reporting after the close that almost gets lost in the shuffle with so many behemoths on the calendar this week. Investors can listen to the SBUX call to get a sense of how the company’s been dealing with various state lockdowns and reopenings. They might also get word on whether its huge international business, especially in China, has started to reflect the bigger economic growth seen there recently. Tomorrow morning get ready for some more big names, including Abbott Laboratories (NYSE: ABT) and Boeing Co (NYSE: BA). Boeing’s earnings will be the first for the company since the 737 MAX began flying again. Tomorrow afternoon is the big showdown as TSLA, AAPL, and FB all come to the table after the close. Also, tomorrow brings the close of the Federal Open Market Committee (FOMC) meeting and the latest economic observations from Fed Chairman Jerome Powell. If you’re bored Wednesday afternoon, you can’t blame it on the market. One thing Monday’s quick early reversal from the opening rally might remind people of is how important it is to look at the warning signs when they flash. Bonds and volatility were both higher along with stocks at the start of yesterday’s session. When you see that combination, it often means stocks are on a leash. Consider keeping an eye on 25 for the VIX and 1% for the 10-year Treasury yield. Penetration above that on VIX or below that on yield could be another warning sign to bullish stock market investors. CHART OF THE DAY: BONDS SPOIL BANKS’ PARTY. The bond market has been climbing recently, taking the 10-year Treasury yield (TNX—candlestick) down to nearly three-week lows. Falling yields can take the starch out of the Financial sector (IXM—purple line), and that’s what apparently happened over the last few days. Data Sources: S&P Dow Jones Indices, CME Group. Chart source: The thinkorswim® platform from TD Ameritrade. For illustrative purposes only. Past performance does not guarantee future results. Not a Bad Problem: Some companies have trouble generating cash flow. Others (very few) have the opposite problem: Too much cash. Apple Inc (NASDAQ: AAPL), which reports tomorrow, is part of that small crowd. The total cash trove stood at roughly $192 billion at the end of the company’s fiscal Q4. AAPL returned nearly $22 billion to shareholders in the form of buybacks and dividends. Investors can expect to continue to see more of that ahead, according to Loup Ventures, which estimates an additional $73 billion will be returned in coming years. “The challenge is that the company is generating so much net income that the road to net cash neutral is long and slow,” Loup Ventures wrote. “Apple has generated $57.4 billion in net income over the past four quarters and returned $90.2 billion in capital in a most tumultuous of years. “At this pace, it will take the company two to three years to be net cash neutral,” the report added. “In the end, Apple has a good problem when it comes to cash—a gravy train of cash returning to investors, which is not fully appreciated.” Stay tuned. Inflation on Doorstep? Did you hear that knock on the front door? One thing that could eventually show up is a little inflation, especially if there’s another big stimulus. As more money hits the system, at some point one would expect a bit of inflation. Maybe it will be more likely in the second half of the year if we get back to normal and people return to their offices and have other opportunities to spend. A lot of the country is still on lockdown and that means there’s only so much spending people can do. If you’re wondering about sector impact from possible inflation, it’s often thought that Consumer Staples and Utilities tend to do better in an inflationary environment. We’ll get a look this Friday at Personal Consumption Expenditure (PCE) prices for December. This report, which the Fed closely watches, showed a tepid 1.1% year-over-year rise in November. Home Renovations: If new spending is driving prices higher and causing the recent manufacturing boom showing up in recent statistics, some of it might be happening in the home furnishings and appliances market. People stuck at home tend to spend on their homes, or at least it seems to be the case. It will be interesting to see if this theory gets more backing when Whirlpool Corporation (NYSE: WHR) reports this week and Home Depot Inc (NYSE: HD) comes out later in the earnings season. Don’t forget Wayfair Inc (NYSE: W), the online furniture retailer whose stock has kind of leveled off recently after that big surge in mid-2020. The company recently raised wages, not a bad sign at all. However, rising wages across more industries could also increase inflation concerns. So far, wage growth has been good but not great. Investors get an update on that early next month when the next payrolls data roll out. TD Ameritrade® commentary for educational purposes only. Member SIPC. Photo by M. B. M. on Unsplash See more from BenzingaClick here for options trades from BenzingaRevenue And Regulatory Risk: Facebook Prepares To Open The Books On Q4Tesla Shares Near Record Territory Ahead Of Q4 Earnings Report© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • J&J Pops On Quarterly Beat, Will 'Soon' Release Covid Vaccine Test Results

    Johnson & Johnson beat fourth-quarter estimates and said it would "soon" release pivotal test results for its coronavirus vaccine — leading JNJ stock to pop Tuesday.

    View More →